Cover Image
市場調查報告書

腫瘤/抗癌藥的南美·中東·非洲市場:機會及預測 (2014∼2021年)

LAMEA Oncology/Anti-cancer drugs Market - Opportunities and Forecasts, 2014 - 2021

出版商 Allied Market Research 商品編碼 354613
出版日期 內容資訊 英文 108 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
腫瘤/抗癌藥的南美·中東·非洲市場:機會及預測 (2014∼2021年) LAMEA Oncology/Anti-cancer drugs Market - Opportunities and Forecasts, 2014 - 2021
出版日期: 2016年02月01日 內容資訊: 英文 108 Pages
簡介

南美·中東·非洲的癌症治療藥市場預測2021年前將達到170億72,20萬美元。預計主要抗癌藥的專利失效促成癌症生技仿製藥市場成長將推動該市場的成長。再加上生物學的治療與其高功效與對標的作用,預測將以年複合成長率12.2%之最快速度成長。

本報告提供南美·中東·非洲的腫瘤/抗癌藥市場現狀與到2021年前的成長預測,提供您各治療法,癌症各類型,及各國趨勢,加上市場趨勢與課題,並彙整主要企業的簡介等資訊。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 新免疫腫瘤藥物開發
  • 主要調查結果
  • 法律規章
  • 償付方案
  • 促進要素
  • 阻礙要素
  • 機會

第4章 南美·中東·非洲的腫瘤/抗癌藥市場:各治療法

  • 化療
  • 標靶治療
  • 免疫治療
  • 荷爾蒙治療
  • 其他

第5章 南美·中東·非洲的腫瘤/抗癌藥市場:癌症各類型

  • 血液癌症
  • 乳癌
  • 消化器官系統癌症
  • 前列腺癌
  • 呼吸系統/肺癌
  • 皮膚癌
  • 其他

第6章 南美·中東·非洲的腫瘤/抗癌藥市場:各國

  • 巴西
  • 阿根廷
  • 奈及利亞
  • 南非
  • 伊拉克
  • 伊朗
  • 阿爾及利亞
  • 沙烏地阿拉伯
  • 埃及
  • 其他

第7章 企業簡介

  • Amgen Inc.
  • AstraZeneca PLC.
  • Roche Diagnostics
  • GlaxoSmithKline PLC
  • Merck & Company
  • Novartis AG
  • AbbVie Inc.
  • Sanofi
  • EIMC United Pharmaceuticals (EUP)
  • Actavis plc

圖表

目錄

Title: LAMEA Oncology/Anti-cancer drugs Market by Therapeutic Modalities (Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy) and Cancer Types (Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Respiratory/Lung Cancer, Skin Cancer) - Opportunity Analysis and Industry Forecast, 2014 - 2021.

Oncology/Anti-cancer drugs are used for treating various cancer types for improving and prolonging a patients survival time. Biological drugs, based on monoclonal antibodies (mAbs) would emerge as a preferred option for treating various cancer types, especially blood cancer (leukaemia). The rising incidence and prevalence of various cancer types, new cancer treatments and growing importance of biological and targeted drug therapies, are driving the market growth of LAMEA oncology/anti-cancer drugs. In addition, increasing demand of anti-cancer drugs for the treatment of ageing population, rising government funds and improved treatment results, are major factors boosting the market growth. However, the high cost involved in new drug development, coupled with threat of failure and adverse effects associated with anti-cancer drugs therapies, would restrain the growth of the LAMEA market. Moreover, accessibility of anti-cancer drugs incurred by high cost, is a major challenge that is expected to further impede the performance of anti-cancer drugs in LAMEA region. Nevertheless, commercialization of advanced therapeutics, such as targeted therapies and immunotherapies (biologic therapies) would reduce the negative influence of restraints and fuel the market growth.

The LAMEA oncology drugs market is segmented into therapeutic modalities, cancer types and countries. Therapeutic modalities segment is further categorized into chemotherapy, targeted therapy, immunotherapy (biologic therapy), hormonal therapy and others. The LAMEA oncology drugs market is expected to reach $17,072.2 million by 2021. Patent expiration of key anti-cancer drugs such as Herceptin (Patent Expiration: EU-2014; US-2019), Erbitux (Patent Expiration: EU-2014; US-2016), Rituxan (Patent Expiration: EU-2013; US-2018) and Avastin (Patent Expiration: EU-2018; US-2019), is expected to boost the growth of cancer biosimilars market by 2021. Further, the biological therapy is the fastest growing segment at a CAGR of 12.2%, throughout the analysis period, on account of high efficacy and target specific action. Moreover, blood cancer drugs market was the largest revenue generating application segment in 2015, owing to the high cost of drugs (immunotherapies), used for the treatment of blood cancer.

Based on countries the LAMEA region is segmented into nine countries named Brazil, Argentina, Nigeria, South Africa, Iraq, Iran, Algeria, Saudi Arabia and Egypt. Brazil dominates the LAMEA market closely followed by Argentina, owing to rising incidence of cancer, high expenditure and gross national income (GNI) of Brazil specifically. In addition, LAMEA market is poised to grow at a promising CAGR of 8.6% during the forecast period. This high growth rate is majorly attributed to the increasing awareness towards advanced therapies, namely immunotherapies and increase in per capita healthcare spending.

The key companies profiled in the report include Amgen Inc., AstraZeneca Plc., Roche Diagnostics, GlaxoSmithKline PLC, Merck & Co., Novartis AG, AbbVie Inc. Sanofi, EIMC United Pharmaceuticals (EUP) and Actavis plc.

KEY BENEFITS:

  • The report provides quantitative analysis of the current market and estimations through 2014-2021 that assists in identifying the prevailing market opportunities.
  • The report helps in understanding the strategies adopted by various companies for gaining market share in the anti-cancer drugs market.
  • The report provides a comprehensive analysis of factors that drive and restrict the growth of the LAMEA anti-cancer drugs market.
  • Market conditions of anti-cancer drugs market across LAMEA region are comprehensively analyzed.
  • Competitive intelligence highlights the business practices followed by leading market players across various geographies.
  • SWOT analysis enables to study the internal environment of the leading companies for strategy formulation.

LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET KEY SEGMENTS:

LAMEA oncology/anti-cancer drugs market is segmented into therapeutic modalities, cancer types and countries.

By Therapeutic modalities

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy
  • Others

By Cancer Types

  • Blood Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Respiratory/Lung Cancer
  • Skin Cancer
  • Other Cancers

By Countries

  • Brazil
  • Argentina
  • Nigeria
  • South Africa
  • Iraq
  • Iran
  • Algeria
  • Saudi Arabia
  • Egypt
  • Other LAMEA countries

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits
  • 1.3. Key market segment
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Development of novel immuno-oncology drug products
  • 3.3. Key findings
    • 3.3.1. Top impacting factors
    • 3.3.2. Top investment pockets
    • 3.3.3. Top winning strategies
  • 3.4. Government regulations
    • 3.4.1. Regulations in Middle East
  • 3.5. Reimbursement scenario
    • 3.5.1. Reimbursement in Middle East
  • 3.6. Drivers
    • 3.6.1. Rising incidence and prevalence of various cancer types
    • 3.6.2. Growing importance of biological and targeted drug therapies
    • 3.6.3. Increasing funding and aid from public and private sector
  • 3.7. Restraints
    • 3.7.1. High cost of drug development and threat of failure
    • 3.7.2. Adverse effects of cancer drug therapy
  • 3.8. Opportunities
    • 3.8.1. Advancement of anti-cancer drugs research
    • 3.8.2. Healthcare and medical awareness

CHAPTER 4: LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES,2014-2021

  • 4.1. Chemotherapy
    • 4.1.1. Market size and forecast
  • 4.2. Targeted therapy
    • 4.2.1. Market size and forecast
  • 4.3. Immunotherapy (biologics therapy)
    • 4.3.1. Market size and forecast
  • 4.4. Hormonal therapy
    • 4.4.1. Market size and forecast
  • 4.5. Others
    • 4.5.1. Market size and forecast

CHAPTER 5: LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY CANCER TYPES,2014-2021

  • 5.1. Blood cancer
    • 5.1.1. Market size and forecast
  • 5.2. Breast cancer
    • 5.2.1. Market size and forecast
  • 5.3. Gastrointestinal cancer
    • 5.3.1. Market size and forecast
  • 5.4. Prostate cancer
    • 5.4.1. Market size and forecast
  • 5.5. Respiratory/lung cancer
    • 5.5.1. Market size and forecast
  • 5.6. Skin cancer
    • 5.6.1. Market size and forecast
  • 5.7. Other cancers
    • 5.7.1. Trends in treatment of other cancer types
    • 5.7.2. Market size and forecast

CHAPTER 6: LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY COUNTRIES,2014-2021

  • 6.1. Brazil
    • 6.1.1. Market size and forecast
  • 6.2. Argentina
    • 6.2.1. Market size and forecast
  • 6.3. Nigeria
    • 6.3.1. Market size and forecast
  • 6.4. South Africa
    • 6.4.1. Market size and forecast
  • 6.5. Iraq
    • 6.5.1. Market size and forecast
  • 6.6. Iran
    • 6.6.1. Market size and forecast
  • 6.7. Algeria
    • 6.7.1. Market size and forecast
  • 6.8. Saudi Arabia
    • 6.8.1. Market size and forecast
  • 6.9. Egypt
    • 6.9.1. Market size and forecast
  • 6.10. Other LAMEA countries
    • 6.10.1. Market size and forecast

CHAPTER 7: COMPANY PROFILES

  • 7.1. Amgen Inc.
    • 7.1.1. Company overview
    • 7.1.2. Business performance
    • 7.1.3. Operating business segment overview
    • 7.1.4. Key strategies and development
    • 7.1.5. SWOT analysis
  • 7.2. AstraZeneca PLC.
    • 7.2.1. Company overview
    • 7.2.2. Business performance
    • 7.2.3. Key strategies and development
    • 7.2.4. SWOT analysis and strategic conclusions
  • 7.3. Roche Diagnostics
    • 7.3.1. Company overview
    • 7.3.2. Operating business segment overview
    • 7.3.3. Business performance
    • 7.3.4. Key strategies moves and development
    • 7.3.5. SWOT analysis
  • 7.4. GlaxoSmithKline PLC
    • 7.4.1. Company overview
    • 7.4.2. Operating business segment overview
    • 7.4.3. Business performance
    • 7.4.4. Key strategies move and development
    • 7.4.5. SWOT Analysis
  • 7.5. Merck & Company
    • 7.5.1. Company overview
    • 7.5.2. Operating business segment overview
    • 7.5.3. Business performance
    • 7.5.4. Key strategies move and development
    • 7.5.5. SWOT analysis
  • 7.6. Novartis AG
    • 7.6.1. Company overview
    • 7.6.2. Operating business segment overview
    • 7.6.3. Business performance
    • 7.6.4. Key strategies move and development
    • 7.6.5. SWOT analysis
  • 7.7. AbbVie Inc.
    • 7.7.1. Company overview
    • 7.7.2. Business performance
    • 7.7.3. Strategic moves and developments
    • 7.7.4. SWOT analysis
  • 7.8. Sanofi
    • 7.8.1. Company overview
    • 7.8.2. Operating business segment overview
    • 7.8.3. Business performance
    • 7.8.4. Key strategies move and development
    • 7.8.5. SWOT analysis
  • 7.9. EIMC United Pharmaceuticals (EUP)
    • 7.9.1. Company overview
    • 7.9.2. Operating business segment overview
    • 7.9.3. Key strategies move and development
    • 7.9.4. SWOT analysis
  • 7.10. Actavis plc
    • 7.10.1. Company overview
    • 7.10.2. Operating business segment overview
    • 7.10.3. Business performance
    • 7.10.4. Key strategies move and development
    • 7.10.5. SWOT analysis

List of Tables

  • TABLE 1: INTERNATIONAL DISEASE CLASSIFICATION CODES AND DESCRIPTION OF CANCER DIAGNOSES
  • TABLE 2: LAMEA ESTIMATED INCIDENCE AND PREVALENCE OF ALL CANCER TYPES, (2012)
  • TABLE 3: LIST OF BIOLOGICAL AND TARGETED DRUGS WITH THEIR REVENUE IN 2013 ($MILLION)
  • TABLE 4: LIST OF COLLABORATIONS AND ACQUISITIONS FOR DEVELOPMENT OF CANCER DRUGS
  • TABLE 5: LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2014 2021 ($MILLION)
  • TABLE 6: LAMEA CHEMOTHERAPY DRUGS MARKET, 2014 2021 ($MILLION)
  • TABLE 7: LAMEA TARGETED THERAPY DRUGS MARKET, 2014 2021 ($MILLION)
  • TABLE 8: LAMEA IMMUNOTHERAPY DRUGS MARKET, 2014 2021 ($MILLION)
  • TABLE 9: LAMEA HORMONAL THERAPY DRUGS MARKET, 2014 2021 ($MILLION)
  • TABLE 10: LAMEA OTHER DRUGS MARKET, 2014 2021 ($MILLION)
  • TABLE 11: LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY CANCER TYPES, 2014 2021 ($MILLION)
  • TABLE 12: LAMEA BLOOD CANCER MARKET, 2014 2021 ($MILLION)
  • TABLE 13: LAMEA BREAST CANCER MARKET, 2014 2021 ($MILLION)
  • TABLE 14: LAMEA GASTROINTESTINAL CANCER MARKET, 2014 2021 ($MILLION)
  • TABLE 15: LAMEA PROSTATE CANCER MARKET, 2014 2021 ($MILLION)
  • TABLE 16: LAMEA RESPIRATORY/LUNG CANCER MARKET, 2014 2021 ($MILLION)
  • TABLE 17: LAMEA SKIN CANCER MARKET, 2014 2021 ($MILLION)
  • TABLE 18: LAMEA OTHER CANCER MARKET, 2014 2021 ($MILLION)
  • TABLE 19: LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY COUNTRIES, 2014 2021 ($MILLION)
  • TABLE 20: BRAZIL ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
  • TABLE 21: ARGENTINA ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
  • TABLE 22: NIGERIA ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
  • TABLE 23: SOUTH AFRICA ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
  • TABLE 24: IRAQ ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
  • TABLE 25: IRAN ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
  • TABLE 26: ALGERIA ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
  • TABLE 27: SAUDI ARABIA ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
  • TABLE 28: EGYPT ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
  • TABLE 29: EGYPT ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
  • TABLE 30: AMGEN INC. SNAPSHOT
  • TABLE 31: ASTRAZENECA SNAPSHOT
  • TABLE 32: ROCHE DIAGNOSTICS SNAPSHOT
  • TABLE 33: ROCHE DIAGNOSTICS OPERATING SEGEMENTS
  • TABLE 34: GLAXOSMITHKLINE PLC SNAPSHOT
  • TABLE 35: GLAXOSMITHKLINE PLC OPERATING SEGEMENTS
  • TABLE 36: MERCK & COMPANY SNAPSHOT
  • TABLE 37: MERCK & CO. OPERATING SEGEMENTS
  • TABLE 38: NOVARTIS AG SNAPSHOT
  • TABLE 39: NOVARTIS AG OPERATING SEGEMENTS
  • TABLE 40: ABBVIE INC. SNAPSHOT
  • TABLE 41: SANOFI SNAPSHOTS
  • TABLE 42: SANOFI OPERATING SEGEMENTS
  • TABLE 43: EIMC UNITED PHARMA SNAPSHOTS
  • TABLE 44: ACTAVIS CORPORATION SNAPSHOTS

List of Figures

  • FIG. 1: TOP FACTORS IMPACTING ANTI-CANCER DRUGS MARKET (2014-2021)
  • FIG. 2: TOP INVESTMENT POCKETS OF ONCOLOGY/ANTI-CANCER DRUGS MARKET (2014)
  • FIG. 3: TOP WINNING STRATEGIES FOR GLOBAL CANCER DRUG MARKET (2011-2015)
  • FIG. 4: TOP WINNING STRATEGIES BY SUBTYPE (2011-2015)
  • FIG. 5: PERCENTAGE (%) OF ALL NEW CANCERS CASES DIAGNOSED IN 2012
  • FIG. 6: LAMEA CHEMOTHERAPY DRUGS MARKET, 2014 2021 ($MILLION)
  • FIG. 7: LAMEA TARGETED THERAPY DRUGS MARKET, 2014 2021 ($MILLION)
  • FIG. 8: LAMEA IMMUNOTHERAPY DRUGS MARKET, 2014 2021 ($MILLION)
  • FIG. 9: LAMEA HORMONAL THERAPY DRUGS MARKET, 2014 2021 ($MILLION)
  • FIG. 10: LAMEA OTHER DRUGS MARKET, 2014 2021 ($MILLION)
  • FIG. 11: LAMEA BLOOD CANCER DEATH RATE (PER 100,000), (2014)
  • FIG. 12: LAMEA BLOOD CANCER MARKET, 2014 2021 ($MILLION)
  • FIG. 13: LAMEA BREAST CANCER DEATH RATE (PER 100,000), 2014
  • FIG. 14: LAMEA BREAST CANCER MARKET, 2014 2021 ($MILLION)
  • FIG. 15: LAMEA GASTROINTESTINAL CANCER DEATH RATE (PER 100,000), 2014
  • FIG. 16: LAMEA GASTROINTESTINAL CANCER MARKET, 2014 2021 ($MILLION)
  • FIG. 17: LAMEA PROSTATE CANCER DEATH RATE (PER 100,000), 2014
  • FIG. 18: LAMEA PROSTATE CANCER MARKET, 2014 2021 ($MILLION)
  • FIG. 19: LAMEA RESPIRATORY/LUNG CANCER DEATH RATE (PER 100,000), 2014
  • FIG. 20: LAMEA RESPIRATORY/LUNG CANCER MARKET, 2014 2021 ($MILLION)
  • FIG. 21: LAMEA SKIN CANCER DEATH RATE (PER 100,000), 2014
  • FIG. 22: LAMEA SKIN CANCER MARKET, 2014 2021 ($MILLION)
  • FIG. 23: LAMEA OTHER CANCER MARKET, 2014 2021 ($MILLION)
  • FIG. 24: AMGEN INC. REVENUE BY GEOGRAPHY (2014)
  • FIG. 25: AMGEN INC. REVENUE BY PRODUCT PORTFOLIO (2014)
  • FIG. 26: SWOT ANALYSIS OF AMGEN INC.
  • FIG. 27: FINANCIAL REVENUES BY GEOGRAPHY (2014)
  • FIG. 28: FINANCIAL REVENUES BY YEAR, 2014 ($MILLION)
  • FIG. 29: SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
  • FIG. 30: ROCHE DIAGNOSTICS BY BUSINESS UNITS (2014)
  • FIG. 31: SWOT ANALYSIS OF ROCHE DIAGNOSTICS
  • FIG. 32: GLAXOSMITHKLINE PLC REVENUE BY GEOGRAPHY (2014)
  • FIG. 33: GLAXOSMITHKLINE PLC REVENUE BY BUSINESS SEGMENTS (2014)
  • FIG. 34: SWOT ANALYSIS OF GLAXOSMITHKLINE PLC
  • FIG. 35: MERCK & CO. REVENUE BY GEOGRAPHY (2014)
  • FIG. 36: SWOT ANALYSIS OF MERCK & COMPANY
  • FIG. 37: NOVARTIS AG REVENUE BY GEOGRAPHY (2014)
  • FIG. 38: NOVARTIS AG REVENUE BY BUSINESS SEGMENTS (2014)
  • FIG. 39: SWOT ANALYSIS OF NOVARTIS AG
  • FIG. 40: NET SALES REVENUES OF ABBVIE BY GEOGRAPHY, 2014 ($MILLION)
  • FIG. 41: SWOT ANALYSIS OF ABBVIE
  • FIG. 42: SANOFI REVENUE BY GEOGRAPHIES (2014)
  • FIG. 43: SANOFI REVENUE BY BUSINESS SEGMENTS (2014)
  • FIG. 44: SWOT ANALYSIS OF SANOFI
  • FIG. 45: SWOT ANALYSIS OF EUP
  • FIG. 46: ACTAVIS CORPORATION REVENUE BY PRODUCT SALES (2014)
  • FIG. 47: SWOT ANALYSIS OF ACTAVIS PLC
  • FIG. 34: SWOT ANALYSIS OF INSIDE SECURE
Back to Top